ArticlePLOS digital health2026
Assessment of change in drug-induced parkinsonism in daily-life gait using vision-based machine learning.
Article in PLOS digital health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Drug-induced parkinsonism is a potentially reversible movement disorder that may be subtle and difficult to monitor in residential dementia care. Vision-based machine learning analysis of gait may provide unobtrusive longitudinal monitoring around medication changes. We conducted a two-center cohort study of 61 residents with dementia receiving psychotropic medication. Hallway gait sequences were recorded using ceiling-mounted cameras and converted to three-dimensional body pose. A TabPFN classifier estimated UPDRS-III item 29 gait severity for each walk. We evaluated associations between acute antipsychotic (AP) and antidepressant (AD) dose reduction/cessation (≥50% dose reduction or cessation, 0-21 days after change) and daily mean predicted gait severity using linear mixed-effects models in ever-exposed participants, with complementary equal-weight paired analyses among participants observed in both medication states. In mixed-effects models, acute AP dose reduction/cessation was associated with lower predicted gait severity (β=-0.127, p = 0.022), whereas AD dose reduction/cessation was not (β=-0.060, p = 0.210). Equal-weight paired analyses found no statistically significant participant-average within-person change among paired participants (AP mean change = 0.031, 95% CI [-0.114, 0.176], p = 0.653; AD mean change =-0.021, 95% CI [-0.098, 0.056], p = 0.575), consistent with heterogeneous individual responses. Vision-based monitoring captured within-participant gait variation around psychotropic dose-reduction periods, but findings are associative. Larger prospective studies with documented reasons for medication changes are needed before using such monitoring to guide medication decisions.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.